Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (291-300 of 349) with videos related to

Pageof 35
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapyHeinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
European Heart Journal|January 9, 2021
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trialJaved Butler, Stefan D Anker, Gerasimos Filippatos, et al.
The New England Journal of Medicine|October 15, 2015
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding RiskPhilip Urban, Ian T Meredith, Alexandre Abizaid, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 9, 2021
Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definitionFelice Gragnano, Alessandro Spirito, Noé Corpataux, et al.
BMC Medical Research Methodology|October 18, 2021
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trialsLisa J Woodhouse, Alan A Montgomery, Jonathan Mant, et al.
Circulation. Cardiovascular Interventions|September 17, 2017
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)Binita Shah, Usman Baber, Stuart J Pocock, et al.
Circulation|November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced TrialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure|June 26, 2024
Incremental value of C-reactive protein to the MEESSI acute heart failure risk scoreDesiree Wussler, Maria Belkin, Samyut Shrestha, et al.
Translational Stroke Research|July 29, 2017
Infections Up to 76 Days After Stroke Increase Disability and DeathAnnastazia E Learoyd, Lisa Woodhouse, Laurence Shaw, et al.
Journal of the American College of Cardiology|October 2, 2020
Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary RevascularizationJohn Gregson, Gregg W Stone, Ori Ben-Yehuda, et al.
Pageof 35

Showing results (291-300 of 349) with videos related to

Sort By:
Pageof 35
European Heart Journal. Cardiovascular Pharmacotherapy|June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapyHeinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
European Heart Journal|January 9, 2021
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trialJaved Butler, Stefan D Anker, Gerasimos Filippatos, et al.
The New England Journal of Medicine|October 15, 2015
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding RiskPhilip Urban, Ian T Meredith, Alexandre Abizaid, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 9, 2021
Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definitionFelice Gragnano, Alessandro Spirito, Noé Corpataux, et al.
BMC Medical Research Methodology|October 18, 2021
Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trialsLisa J Woodhouse, Alan A Montgomery, Jonathan Mant, et al.
Circulation. Cardiovascular Interventions|September 17, 2017
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)Binita Shah, Usman Baber, Stuart J Pocock, et al.
Circulation|November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced TrialStefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure|June 26, 2024
Incremental value of C-reactive protein to the MEESSI acute heart failure risk scoreDesiree Wussler, Maria Belkin, Samyut Shrestha, et al.
Translational Stroke Research|July 29, 2017
Infections Up to 76 Days After Stroke Increase Disability and DeathAnnastazia E Learoyd, Lisa Woodhouse, Laurence Shaw, et al.
Journal of the American College of Cardiology|October 2, 2020
Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary RevascularizationJohn Gregson, Gregg W Stone, Ori Ben-Yehuda, et al.
Pageof 35